| Bioactivity | Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. |
| Name | Tilsotolimod |
| CAS | 1948266-37-2 |
| Formula | C223H284N74O115P22S22 |
| Molar Mass | 7228.00 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karime C, Wang J, Woodhead G, et al. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs. 2022;31(1):1-13. [2]. Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021;11(8):1996-2013. [3]. Babiker H, Borazanci E, Subbiah V, et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022;28(23):5079-5087. |
Tilsotolimod
CAS: 1948266-37-2 F: C223H284N74O115P22S22 W: 7228.00
Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.